AI-Powered Marketing Technology Solutions Q4 and FY 2025 Financial Results Conference Call March 31, 2026 NASDAQ: BNZI Disclaimers No Offer or Solicitation This Presentation and any oral statements made in connection with this Presentation do not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities of the Company in any jurisdiction, nor shall there be any sale, issuance or transfer of any securities of the Company in any jurisdiction where, or t ...

TSX: IVN | OTCQX: IVPAF KAMOA-KAKULA 2026 MINERAL RESERVE & MINERAL RESOURCE UPDATE Presentation & Webinar March 31, 2026 DISCLAIMER AND FORWARD-LOOKING STATEMENTS Certain statements in this release constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company, its projects, ...

INSTITUTIONAL PRESENTATION 2025 March 31st, 2026 Telefônica Brasil S.A. Investor Relations ***Este documento está clasificado como USO INTERNO por TELEFÓNICA. ***This document is classified as INTERNAL USE by TELEFÓNICA. DISCLAIMER This presentation may contain forward -looking statements concerning prospects and objectives regarding the capture of synergies, growth of the subscriber base, a breakdown of the various services to be offered and their respective results Our actual results may differ materially ...

HGV Investor Overview M A R C H 2 0 2 6 Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements convey management's expectations as to the future of HGV, and are based on management's beliefs, expectations, assumptions and such plans, estimates, projections and other information available to management at the time ...

Royal Gold (NasdaqGS:RGLD) 2026 Investor Day March 31, 2026 12:30 PM ET Company ParticipantsAlistair Baker - SVP of Investor Relations and Business DevelopmentBill Heissenbuttel - President and CEOBrian MacArthur - Managing DirectorCosmos Chiu - Executive Director of Precious Metals Institutional Equity ResearchDan Breeze - SVP of Corporate DevelopmentJason Hynes - SVP of Strategy and Business DevelopmentJosh Wolfson - Managing Director and Head of Global Mining ResearchKim Bergen - Director of Investor Rel ...

Financial Data and Key Metrics Changes - Total revenue for 2025 was $28.1 million, a slight decrease from $28.3 million in 2024, indicating stability despite operational challenges [12][14] - Fourth quarter revenue decreased by 14.8% to $7.7 million compared to $9.1 million in the prior period, primarily due to the expiration of contracts and lower treatment volumes [11][12] - Gross margin for the fourth quarter was approximately $906 thousand or 12%, down from 35% in Q4 2024, reflecting lower treatment volumes and a shift towards direct patient services [12] - Net loss attributable to the company improved to $631 thousand or $0.09 per diluted share, compared to a net loss of $1.6 million or $0.23 per diluted share in the prior year [12] Business Line Data and Key Metrics Changes - Revenue from direct patient care services increased by 23.7% to $15.5 million, while leasing revenue declined to $12.6 million, reflecting the company's strategic transition [13] - LINAC revenue increased by 35.4% to $11.5 million, while Gamma Knife revenue decreased by 5.5% to $9.2 million, and proton beam radiation therapy revenue declined by 26% to $7.4 million [13] - LINAC treatment sessions more than doubled to 28,147 in 2025, marking the first full year of operations for both Puebla and Rhode Island centers [13] Market Data and Key Metrics Changes - The international business remains a strong contributor, with successful operations in Puebla, Mexico, and leadership positions in Ecuador and Peru [9] - The company is expanding its footprint in international markets, including the development of a new center in Guadalajara, Mexico, expected to begin operations in 2026 [9] Company Strategy and Development Direction - The company is focused on strengthening health system partnerships, which are key to its long-term strategy and operational foundation [4] - A transition towards a direct patient care model is underway, which now represents the majority of revenue and provides a more stable platform for growth [4][6] - Future growth initiatives include increasing treatment volumes, driving operational efficiencies, and expanding through disciplined development [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges such as physician turnover and reimbursement dynamics but emphasized decisive actions taken to address these issues [5][10] - The company is optimistic about 2026, citing a strong foundation for future growth supported by partnerships and expanded clinical capacity [10][47] - Management is engaged with lending partners to enhance capital structure and support long-term growth initiatives [6][15] Other Important Information - The company ended the year with approximately $3.7 million in cash, down from $11.3 million at the end of 2024, primarily due to capital expenditures related to expansion [14][15] - Total debt at year-end was approximately $17.3 million, with discussions ongoing regarding amendments to the credit facility [15] Q&A Session Summary Question: Will the company be able to offset temporary revenue distortions by referring patients between centers in Rhode Island? - Management confirmed that leveraging infrastructure across a larger footprint is part of the strategy in Rhode Island [18][19] Question: What is the timeline for constructing the new facility in Rhode Island and staffing it? - The Bristol facility is expected to come online in late 2027, with staffing initiatives starting several months in advance [20][21] Question: Why were the expired contracts not disclosed earlier? - Management clarified that the expiration of contracts was mentioned in past calls, and the health systems opted to update equipment independently [25][29] Question: Will the company be profitable in 2026? - Management refrained from speculating on profitability for 2026, citing foundational issues that have been addressed [30][32] Question: Is the company constrained from buying back stock due to credit agreements? - Management indicated that a stock buyback program has not been a priority and is unlikely to change under current lender conditions [41]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $28.1 million, a slight decrease from $28.3 million in 2024 [12][14] - Fourth quarter revenue decreased by 14.8% to $7.7 million compared to $9.1 million in the prior period, primarily due to the expiration of three Gamma Knife contracts and lower proton beam radiation therapy volumes [11] - Gross margin for Q4 was approximately $906,000 or 12%, down from 35% in Q4 2024, reflecting lower treatment volumes and a shift towards direct patient services [12] - Net loss attributable to the company improved to $631,000 or $0.09 per diluted share in Q4, compared to a net loss of $1.6 million or $0.23 per diluted share in the prior year [12] Business Line Data and Key Metrics Changes - Revenue from direct patient care services increased by 23.7% to $15.5 million, while leasing revenue declined to $12.6 million [13] - LINAC revenue increased by 35.4% to $11.5 million, while Gamma Knife revenue decreased by 5.5% to $9.2 million, and proton beam radiation therapy revenue declined by 26% to $7.4 million [13] - LINAC treatment sessions more than doubled to 28,147 in 2025, marking the first full year of operations for both Puebla and Rhode Island centers [13] Market Data and Key Metrics Changes - The international business remains a strong contributor, with successful operations in Puebla, Peru, and leadership positions in Ecuador and Peru [9] - The company is developing a new center in Guadalajara, Mexico, expected to begin operations in 2026, which represents significant future opportunity [9] Company Strategy and Development Direction - The company is focused on strengthening health system partnerships, expanding clinical capabilities, and enhancing patient access to advanced cancer care [4] - A strategic transition towards a direct patient care model is underway, which now represents the majority of revenue and provides a stable platform for long-term growth [4][10] - Future priorities include increasing treatment volumes, driving operational efficiencies, and expanding the footprint through disciplined development [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenges in 2025, including physician turnover and reimbursement dynamics, but emphasizes decisive actions taken to address these issues [5][10] - The company is optimistic about 2026, supported by strengthened partnerships and a clear development pipeline [10][48] - Management remains focused on delivering high-quality cancer care and creating long-term value for shareholders [48] Other Important Information - The company ended the year with approximately $3.7 million in cash, down from $11.3 million at the end of 2024, primarily due to capital expenditures related to expansion [14][15] - Total debt at year-end was approximately $17.3 million, with ongoing discussions with lenders regarding amendments and potential restructuring of credit facilities [15] Q&A Session Summary Question: Will the company be able to offset equipment upgrade impacts by referring patients between centers in Rhode Island? - Management confirmed that leveraging infrastructure across a larger footprint is part of the strategy in Rhode Island [18][19] Question: What is the timeline for constructing the new facility in Rhode Island and staffing it? - The Bristol facility is expected to come online in late 2027, followed by the proton facility in 2028, with staffing starting several months in advance [20][21] Question: Why were the expired contracts not disclosed earlier? - Management explained that the expiration of contracts was mentioned in past calls, and the health systems opted to update equipment themselves [25][28] Question: Will the company be profitable in 2026? - Management refrained from speculating on profitability for 2026, emphasizing that foundational issues have been addressed [30][32] Question: Is the company constrained from buying back stock due to credit agreements? - Management indicated that the company has not been interested in a stock buyback program and that current lender conditions make it unlikely to change [40][42]

Hershey Company 2026 Investor Day Summary Company Overview - **Company**: The Hershey Company (NYSE: HSY) - **Event**: 2026 Investor Day - **Date**: March 31, 2026 - **Location**: New York Stock Exchange Core Industry Insights - **Industry**: Snacking and Confectionery - **Market Trends**: The snacking category has shown resilience, maintaining growth rates of 2%-3% even during economic pressures, driven by better-for-you and functional segments as well as emotional categories like chocolate [30][31] Key Strategic Points 1. **Three Cs of Success**: - **Consumer Obsession**: Focus on exceeding consumer expectations [11] - **Customer Partnerships**: Building trust with retail partners for mutual growth [11] - **Colleague Investment**: Investing in employee development and capabilities [11] 2. **Next-Generation Snacking Strategy**: - Hershey aims to lead in the next generation of snacking with a strong foundation for growth [12] - Focus on core brands and innovation, particularly in permissible snacking [13][14] 3. **Investment Focus**: - Significant investments in IT and supply chain modernization to enhance agility and efficiency [13][20] - Portfolio reinvigoration through core innovation and expansion into high-growth areas [13][14] 4. **International Growth**: - Targeting high-growth markets such as Canada, Mexico, Brazil, Europe, and the U.K. [15] - Building a $300 million international business with the Reese's brand [15] 5. **Consumer Trends**: - Increasing focus on health and wellness, with a shift towards premiumization and functional snacks [16] - Emphasis on digital engagement and omnichannel execution to reach Gen Z consumers [16] Financial Performance and Projections - **Revenue Growth**: - Projected organic net revenue growth of 2%-4% for 2026 and 2027, with double-digit EPS growth [27][28] - Long-term balanced revenue growth algorithm targeting 6%-8% EPS growth by 2028 [28] Portfolio and Innovation 1. **Maximizing Core Brands**: - Focus on modernizing brand building and leveraging portfolio effectiveness [30][33] - Plans to scale next billion-dollar brands through targeted innovation [30][33] 2. **Emerging Trends**: - Capitalizing on premiumization, functional snacking, and multisensory experiences [48][49] - Introduction of new product formats and flavors to meet evolving consumer preferences [49][50] 3. **M&A Strategy**: - Targeted acquisitions to fill capability gaps and enter new categories, such as the recent addition of LesserEvil [52] Supply Chain and Operational Excellence - **Supply Chain Modernization**: - Investments in technology and automation to enhance service levels and efficiency [23][24] - Focus on precision demand fulfillment as a competitive advantage [23] Marketing and Commercial Strategy 1. **ONE Hershey Model**: - A unified approach to commercial excellence that integrates the entire snacking portfolio [22][59] - Emphasis on availability, affordability, and activation at retail [57] 2. **Brand Activation**: - Leveraging cultural moments and seasonal events to drive brand engagement and sales [75] - Successful campaigns like Reese's Oreo launch demonstrating effective consumer resonance [36][67] Conclusion - **Future Outlook**: - Hershey is positioned for sustained long-term growth through a diversified portfolio focused on high-growth segments, strategic investments, and a robust supply chain [28][53] - The company aims to capture significant market opportunities while enhancing shareholder value through innovative strategies and operational excellence [28][29]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 decreased by 14.8% to $7.7 million compared to $9.1 million in Q4 2024, primarily due to the expiration of Gamma Knife contracts and lower proton beam radiation therapy volumes [12] - For the full year 2025, total revenue was $28.1 million, slightly down from $28.3 million in 2024 [13] - Gross margin for Q4 2025 was approximately $906 thousand or 12%, down from 35% in Q4 2024, reflecting lower treatment volumes and a shift towards direct patient services [13] - Net loss attributable to the company improved to $631 thousand or $0.09 per diluted share, compared to a net loss of $1.6 million or $0.23 per diluted share in the prior year [13] - Adjusted EBITDA for the full year was $5.5 million, down from $8.9 million in 2024 [16] Business Line Data and Key Metrics Changes - Revenue from direct patient care services increased by 23.7% to $15.5 million, while leasing revenue declined to $12.6 million [14] - LINAC revenue increased by 35.4% to $11.5 million, while Gamma Knife revenue decreased by 5.5% to $9.2 million, and proton beam radiation therapy revenue declined by 26% to $7.4 million [14] - LINAC treatment sessions more than doubled to 28,147 in 2025, marking the first full year of operations for both Puebla and Rhode Island centers [14] Market Data and Key Metrics Changes - The international business remains a strong contributor, with successful operations in Puebla, Mexico, and leadership positions in Ecuador and Peru [10] - The company is developing a new center in Guadalajara, Mexico, expected to begin operations in 2026, which represents significant future opportunity [10] Company Strategy and Development Direction - The company is focused on strengthening health system partnerships, expanding clinical capabilities, and enhancing patient access to advanced cancer care [4] - A transition towards a direct patient care model is underway, which now represents the majority of revenue and provides a stable platform for long-term growth [4] - Future priorities include increasing treatment volumes, driving operational efficiencies, and expanding the footprint through disciplined development [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in 2025, including physician turnover and reimbursement dynamics, but emphasized decisive actions taken to address these issues [5] - The company is optimistic about 2026, citing a strong foundation for future growth supported by partnerships and expanded clinical capacity [11] - Ongoing discussions with lenders regarding capital structure enhancements are constructive, aiming to support long-term growth initiatives [6] Other Important Information - The company ended 2025 with approximately $3.7 million in cash, down from $11.3 million at the end of 2024, primarily due to capital expenditures related to expansion [16] - Total debt at year-end was approximately $17.3 million, with certain financial covenants not met due to lower profitability and higher operating costs [17] Q&A Session Summary Question: Will the company be able to offset revenue declines from expired contracts by referring patients between centers in Rhode Island? - Management confirmed that leveraging infrastructure across a larger footprint is part of the strategy in Rhode Island [21] Question: What is the timeline for constructing the new facility in Rhode Island and staffing it? - The Bristol facility is expected to come online in late 2027, followed by the proton facility in 2028, with staffing initiatives starting several months in advance [22] Question: Why were the expired contracts not disclosed earlier? - Management explained that the expiration of contracts was previously mentioned, and the health systems opted to update their equipment independently [28][31] Question: Will the company be profitable in 2026? - Management refrained from speculating on profitability for 2026, emphasizing that foundational issues have been addressed [35] Question: Is the company constrained from buying back stock due to credit agreements? - Management indicated that the company has not been interested in a stock buyback program and that current lender conditions make it unlikely to change this stance [44]

Investor Day 2026 CAUTIONARY STATEMENTS Forward-Looking Statements: This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements are any statements other than statements of historical fact. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from these statements. Forward-looking statements are often identified by words like "will," "may," "could," "should," "would," "believe," ...